Demonstrates Additive Anti-Cancer Effect in Bladder Cancer In-Vitro Model when Light-Activated Ruvidar(R) is Combined with InterferonToronto, Ontario--(Newsfile Corp. - March 2, 2026) - Theralase® ...

A perspective in The Journal of Clinical Investigation argues that environmental exposures may interact with the gut ...

Dr. Eric Singer reveals the latest advances in kidney cancer care that help patients live longer and maintain quality of life.

Background Concomitant metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in patients with chronic ...

Researchers designed CAR T cells that locally release VEGF-blocking molecules, weakening tumor defenses and boosting immune attack. The therapy slowed tumor growth and improved survival in cancer ...

HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target natural regulatory pockets, today announced the ...

In the phase 3 VERIFY trial, rusfertide was associated with a significantly higher proportion of patients achieving clinical response compared with placebo.

By Vijay Kumar Malesu New research reveals how measles infection disrupts immune memory and increases vulnerability to other infections, reinforcing why high vaccination coverage remains critical to ...

Sepsis remains a major challenge in modern medicine, claiming millions of lives each year. For decades, clinical management has largely focused on suppressing excessive inflammation.

The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...

Severe bacterial pneumonia remains a major cause of death in critically ill patients, largely due to impaired early immune responses.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report full year 2025 financial results on Monday, March 16, ...